Dynavax (DVAX) Tops Q3 EPS by 14c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mail
Get Alerts DVAX Hot Sheet
Price: $15.50 --0%
Financial Fact:
Research and development: 23.23M
Today's EPS Names:
SMXT, NRIX, VFS, More
Financial Fact:
Research and development: 23.23M
Today's EPS Names:
SMXT, NRIX, VFS, More
Join SI Premium – FREE
Dynavax (NASDAQ: DVAX) reported Q3 EPS of $0.10, $0.14 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $69.51 million versus the consensus estimate of $60.3 million.
GUIDANCE:
Dynavax sees FY2023 revenue of $210-220 million, versus the consensus of $224.7 million.
For earnings history and earnings-related data on Dynavax (DVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73
- StoneX Starts SoFi Technologies (SOFI) at Buy
- eBay named Morgan Stanley top pick on live commerce flywheel; stock surges
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
